Protocol for an economic evaluation of the Quitlink randomized controlled trial for accessible smoking cessation support for people with severe mental illness

Sweeney, Rohan, Moodie, Marj, Baker, Amanda L., Borland, Ron, Castle, David, Segan, Catherine, Tumer, Alyna, Attia, John, Kelly, Peter J., Brophy, Lisa, Bonevski, Billie, Williams, Jill M., Baird, Donita, White, Sarah L. and McCarter, Kristen 2019, Protocol for an economic evaluation of the Quitlink randomized controlled trial for accessible smoking cessation support for people with severe mental illness, Frontiers in Psychiatry, vol. 10, doi: 10.3389/fpsyt.2019.00618.

Attached Files
Name Description MIMEType Size Downloads

Title Protocol for an economic evaluation of the Quitlink randomized controlled trial for accessible smoking cessation support for people with severe mental illness
Author(s) Sweeney, Rohan
Moodie, MarjORCID iD for Moodie, Marj orcid.org/0000-0001-6890-5250
Baker, Amanda L.
Borland, Ron
Castle, David
Segan, Catherine
Tumer, Alyna
Attia, John
Kelly, Peter J.
Brophy, Lisa
Bonevski, Billie
Williams, Jill M.
Baird, Donita
White, Sarah L.
McCarter, Kristen
Journal name Frontiers in Psychiatry
Volume number 10
Article ID ARTN 618
Total pages 10
Publisher Frontiers Media
Place of publication Lausanne, Switzerland
Publication date 2019-09-03
ISSN 1664-0640
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Psychiatry
smoking
smoking cessation
mental illness
quitline
peer worker
economic evaluation
cost-effectiveness
TOBACCO CESSATION
INDIVIDUALS
TELEPHONE
DISORDER
BURDEN
Summary Introduction: Smoking is a major cause of disease burden and reduced quality of life for people with severe mental illness (SMI). It places significant resource pressure on health systems and financial stress on smokers with SMI (SSMI). Telephone-based smoking cessation interventions have been shown to be cost effective in general populations. However, evidence suggests that SSMI are less likely to be referred to quitlines, and little is known about the effectiveness and cost effectiveness of such interventions that specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking cessation support for SSMI aims to bridge this gap. This paper describes the protocol for evaluating the cost effectiveness of Quitlink. Methods: Quitlink will be implemented in the Australian setting, utilizing the existing mental health peer workforce to link SSMI to a tailored quitline service. The effectiveness of Quitlink will be evaluated in a clustered randomized controlled trial. A cost-effectiveness evaluation will be conducted alongside the Quitlink clustered randomized controlled trial (RCT) with incremental cost-effectiveness ratios (ICERs) calculated for the cost (AUD) per successful quit and quality adjusted life year (QALY) gained at 8 months compared with usual care from both health care system and limited societal perspectives. Financial implications for study participants will also be investigated. A modeled cost-effectiveness analysis will also be conducted to estimate future costs and benefits associated with any treatment effect observed during the trial. Results will be extrapolated to estimate the cost effectiveness of rolling out Quitlink nationally. Sensitivity analyses will be undertaken to assess the impact on results from plausible variations in all modeled variables. Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer worker and quitline workforces and tailors quitline support specifically to provide that increased cessation support. Given Quitlink engages these existing skilled workforces, it is hypothesized that, if found to be effective, it will also be found to be both cost effective and scalable. This protocol describes the economic evaluation of Quitlink that will assess these hypotheses.Ethics and dissemination: Full ethics clearances have been received for the methods described below from the University of Newcastle (Australia) Human Research Ethics Committee (H-2018-0192) and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154). The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12619000244101). Participant consent is sought both to participate in the study and to have the study data linked to routine health administrative data on publicly subsidized health service and pharmaceutical use, specifically the Medicare Benefits and Pharmaceutical Benefits Schemes (MBS/PBS). Trial findings (including economic evaluation) will be published in peer reviewed journals and presented at international conferences. Collected data and analyses will be made available in accordance with journal policies and study ethics approvals. Results will be presented to relevant government authorities with an interest in cost effectiveness of these types of interventions.
Language eng
DOI 10.3389/fpsyt.2019.00618
Indigenous content off
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2019 Sweeney, Moodie, Baker, Borland, Castle, Segan, Turner, Attia, Kelly, Brophy, Bonevski, Williams, Baird, White and McCarter
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30129905

Document type: Journal Article
Collections: Faculty of Health
Population Health
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 12 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 18 Sep 2019, 08:07:08 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.